Square Pharmaceuticals PLC, the country’s leading pharmaceutical manufacturer, maintained its steady upward growth trajectory, posting higher revenue and profit for the first quarter of the fiscal year 2026–27 (July–September 2026) compared to the corresponding periods of previous years.
According to the unaudited consolidated financial statements for the three months ended 30 September 2026, the company’s net revenue rose 4% to Tk2,243.90 crore, up from Tk2,158.66 crore recorded in July–September 2025.
This top-line expansion contributed to a higher gross profit of Tk1,218.46 crore, compared to Tk1,124.35 crore in the same period a year earlier.
Net profit after tax for the first quarter of FY27 grew to Tk7,77.59 crore, reflecting a steady increase by 5% from Tk740.45 crore reported in Q1 FY26. Consequently, basic earnings per share (EPS) improved to Tk8.77 for July–September 2026, up from Tk8.35 in the corresponding period of the previous fiscal year.
The company’s balance sheet strength also expanded further during the quarter. Consolidated Net Asset Value (NAV) per share increased to Tk187.35 as of 30 September 2026, compared to Tk178.99 at the close of June 2026.
Meanwhile, net operating cash flow per share (NOCFPS) stood at Tk5.49 for the reporting quarter, compared to Tk7.55 in the same period a year earlier, reflecting normal operational working capital adjustments.
The consistent quarterly earnings growth builds upon Square Pharma’s robust annual performance in FY26, during which the drugmaker crossed the milestone of Tk2,770 crore in annual profit and declared a 130% cash dividend for its shareholders.
About The Author
